CLSA is pleased to welcome Catalent Biologics into the life sciences community as our newest Strategic Partner
September 3rd, 2020 (South San Francisco) – The California Life Sciences Association (CLSA) is pleased to welcome Catalent Biologics into the life sciences community as our newest Strategic Partner.
Through this partnership, Catalent Biologics will work closely with CLSA to serve all life sciences companies in California with exceptional service and support for members’ biologic development and manufacturing needs. The CLSA and Catalent Biologics teams are committed to working together to increase the productivity of our membership by ensuring the right solutions arrive at the right time to foster innovation where people and patients come first. CLSA Strategic Partners exhibit a higher level of commitment to our community.
“Catalent is a global leader in biologics development and manufacturing and a critical partner in our membership’s ability to deliver products to patients,” said Andrew Setikas, SVP Business Development & Strategy, CLSA, “Their investment in advanced therapy development and manufacturing has set the standard for excellence within the industry.”
“We are very pleased to partner with CLSA and support the biologic development and manufacturing needs of their members,” said Bernie Clark, Vice President, Marketing & Strategy, Catalent Biologics. “CLSA’s diverse member base is a community of innovative companies working hard to improve the lives of patients in California and around the world, and we appreciate the opportunity to work together toward this common goal.”
California Life Sciences Association (CLSA) is the state’s largest and most influential life sciences advocacy and business leadership organization. With offices in Sacramento, San Diego, South San Francisco, Los Angeles and Washington DC, CLSA works closely with industry, government, academia and others to shape public policy, improve access to innovative technologies and grow California’s life sciences economy. CLSA serves biotechnology, pharmaceutical, medical device and diagnostics companies, research universities and institutes, investors and service providers throughout the Golden State.
About Catalent Biologics
Catalent Biologics is a global leader in development, manufacturing and analytical services for new biological entities, cell and gene therapies, biosimilars, sterile injectables, and antibody-drug conjugates. With over 20 years of proven expertise, Catalent Biologics has worked with 600+ mAbs and 80+ proteins, produced 13 biopharmaceutical drugs using GPEx® cell line development technology, and manufactured 35+ commercially approved products. Catalent Cell & Gene Therapy, a unit of Catalent Biologics, is a full-service partner for adeno-associated virus (AAV) vectors and CAR-T immunotherapies, with deep experience in viral vector scale-up and production. Catalent recently acquired MaSTherCell, adding expertise in autologous and allogeneic cell therapy development and manufacturing. Catalent Cell & Gene Therapy has produced 100+ cGMP batches across 70+ clinical and commercial programs. For more information, visit biologics.catalent.com
Catalent is the leading global provider of advanced delivery technologies, development, manufacturing, and clinical supply solutions for drugs, biologics, cell and gene therapies, and consumer health products. With over 85 years serving the industry, Catalent has proven expertise in bringing more customer products to market faster, enhancing product performance and ensuring reliable global clinical and commercial product supply. Catalent employs over 13,900 people, including over 2,400 scientists and technicians, at more than 45 facilities, and in fiscal year 2020 generated over $3 billion in annual revenue. Catalent is headquartered in Somerset, New Jersey. For more information, visit www.catalent.com
More products. Better treatments. Reliably supplied.™